SBH
CRMD icon

Segall Bryant & Hamill’s CorMedix CRMD Stock Holding History

Segall Bryant & Hamill’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-126,675
Closed -$860K – 604
2026
Q1 		$860K Buy
126,675
+65,723
+108% +$486K 0.01% 524
2025
Q4 		$709K Buy
+60,952
New +$674K 0.01% 528

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Segall Bryant & Hamill's CRMD Position: Q2 2026 in Review

Segall Bryant & Hamill sold out of CorMedix (CRMD) in Q2 2026, closing a stake of 126,675 shares — an estimated $860K sold.

Segall Bryant & Hamill first reported a position in CRMD in Q4 2025 and held it in 2 quarters. The position peaked at $860K in Q1 2026. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Segall Bryant & Hamill reported no remaining CorMedix position as of Q2 2026 after selling out during the quarter.
  • Segall Bryant & Hamill sold 126,675 CorMedix shares in Q2 2026, an estimated $860K.
  • Segall Bryant & Hamill first reported a position in CorMedix in Q4 2025 and held it in 2 quarters.
  • Segall Bryant & Hamill's CorMedix position peaked at $860K in Q1 2026.
  • 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.